https://academic.oup.com/ijnp/article/28/Supplement_1/i351/8009512?searchresult=1
“Published: 12 February 2025”
“Results”
“The high retention rate [82.5% after 6-month] and the low incidence of adverse dropouts [1.9%] indicate the good tolerability of evenamide. Interim analyses at 6-month (mITT=156) and 1-year for the first cohort of 100 patients, indicated that a large proportion of patients improve to an extent that they no longer meet the operational severity criteria for TRS; and a significant proportion can be considered ‘responders’ based on TRRIP definition (>=20% improvement on PANSS maintained for >=12 weeks [8]). Comparison of results available after 6-week, 6-month, and 1-year are likely to indicate a pattern of unique efficacy over time. Furthermore, increasing and long-lasting improvement was observed in all efficacy scales [9,10], with the largest improvement in the 15 and 30 mg bid dose groups. Full, 1-year results, available by the time of the Congress, will be presented demonstrating remarkable efficacy of evenamide at 1-year in TRS patients.”